Skip to main content
OpenTrials

Clinical trial condition

Triple Negative Locally Advanced Non-resectable Breast Cancer

Explore clinical trials studying Triple Negative Locally Advanced Non-resectable Breast Cancer. Study availability and eligibility vary by location and protocol.

2 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Triple Negative Locally Advanced Non-resectable Breast Cancer trial results

Recruiting

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

NCT06827613

Conditions
HR+, HER2-, Advanced Breast Cancer, Triple Negative Locally Advanced Non-resectable Breast Cancer
Locations
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UCLA Health Los Angeles, California, United States
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
View Trial Details
Completed

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

NCT00633464

Conditions
Breast Diseases, Breast Neoplasms, Metastatic Breast Cancer, +5 more
Locations
  • Local Institution Graz, Austria
  • Local Institution Vienna, Austria
  • Local Institution Brno, Czechia
  • Local Institution Prague, Czechia
View all 19 locations
View Trial Details

Related conditions